Human Patents (Class 424/142.1)
-
Publication number: 20140170108Abstract: The present invention provides sustained release and long acting forms of peptide therapeutic, particularly Interleukin-1 receptor antagonist (IL-1ra), including multimeric forms of IL-1ra, including variants of IL-1ra which are capable of multimerising, and compositions comprising the long acting and multimeric forms of IL-1ra, and a process of preparation thereof. The present invention also provides compositions comprising the multimeric forms of IL-1ra, including IL-1raK, KIL-1ra and KIL-1raK, which are effective in inhibiting, treating and/or ameliorating rheumatoid disease, inflammatory diseases or disorders, autoinflammatory disorders or conditions resulting from adverse effects of Interleukin-1 (IL-1). Methods of treating a subject comprising administering the composition comprising the multimeric forms of IL-1ra are also provided.Type: ApplicationFiled: May 18, 2012Publication date: June 19, 2014Inventors: Avadhesha Surolia, Shweta Pasi, Sarika Gupta
-
Publication number: 20140170156Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: November 7, 2013Publication date: June 19, 2014Applicant: GENMAB A/SInventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
-
Patent number: 8753633Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: June 15, 2012Date of Patent: June 17, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20140161811Abstract: The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV).Type: ApplicationFiled: May 3, 2013Publication date: June 12, 2014Applicant: Sutter West Bay HospitalsInventors: Charles Cobbs, Liliana Soroceanu
-
Publication number: 20140161769Abstract: The present invention features a method of treating or reducing the likelihood of an inflammatory autoimmune disorder (e.g., systemic lupus erythematosus (SLE)) or a kidney disorder (e.g., glomerulonephritis) in a subject by administering an inhibitor of calcium/calmodulin-dependent protein kinase type IV (CaMKIV). The invention additionally features methods of diagnosing a subject with SLE or a kidney disorder by determining the level or biological activity of a CaMKIV nucleic acid or polypeptide in a sample from a subject. Also included in the invention are methods for identifying compounds that inhibit CaMKIV for the treatment of an inflammatory autoimmune disorder (e.g., SLE) or a kidney disorder (e.g., glomerulonephritis).Type: ApplicationFiled: July 8, 2013Publication date: June 12, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: George C. Tsokos, Yuang-Taung Juang, Chun-Shin Hahn
-
Patent number: 8748475Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.Type: GrantFiled: August 3, 2011Date of Patent: June 10, 2014Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Simon K. Mencher
-
Patent number: 8747854Abstract: The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treating hidradenitis suppurativa in a subject.Type: GrantFiled: June 3, 2011Date of Patent: June 10, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Martin M. Okun, Thomas C. Harris
-
Patent number: 8741296Abstract: The present invention features a polypeptide, such as an antibody produced by the hybridoma SAM-6 and its use in the treatment and diagnosis of neoplasms.Type: GrantFiled: March 23, 2012Date of Patent: June 3, 2014Assignee: Patrys LimitedInventors: Heinz Peter Vollmers, Hans-Konrad Müller-Hermelink
-
Patent number: 8741289Abstract: Novel antibodies and antigen binding fragments that specifically binds to S?glec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of S?glec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of S?glec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: October 6, 2010Date of Patent: June 3, 2014Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20140147382Abstract: The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.Type: ApplicationFiled: January 30, 2014Publication date: May 29, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans HANSEN
-
Publication number: 20140147438Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.Type: ApplicationFiled: November 21, 2013Publication date: May 29, 2014Applicant: LABRYS BIOLOGICS, INC.Inventors: JOERG ZELLER, KRISTIAN T. POULSEN, YASMINA NOUBIA ABDICHE, JAUME PONS, SIERRA JONES COLLIER, ARNON ROSENTHAL
-
Patent number: 8734799Abstract: Disclosed herein are methods and compositions for treating cancer. In particular, the in vivo efficacy of unconjugated anti-TfR antibodies, such as ch128.1, are disclosed herein.Type: GrantFiled: April 11, 2011Date of Patent: May 27, 2014Assignee: The Regents of the University of CaliforniaInventors: Manuel L. Penichet, Tracy R. Wells
-
Patent number: 8734791Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.Type: GrantFiled: February 27, 2012Date of Patent: May 27, 2014Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8734789Abstract: The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related diseases such as cancer.Type: GrantFiled: November 12, 2010Date of Patent: May 27, 2014Assignee: The University of North Carolina at Chapel HillInventors: Nancy Klauber DeMore, Cam Patterson, Rajendra Bhati, Bradley G. Bone
-
Publication number: 20140141008Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.Type: ApplicationFiled: January 31, 2014Publication date: May 22, 2014Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
-
Publication number: 20140141006Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: October 16, 2013Publication date: May 22, 2014Applicant: GENMAB A/SInventors: Jan G. J. VAN DE WINKEL, Marcus Antonius VAN DIJK, Edward HALK, Arnout F. GERRITSEN, Jørgen PETERSEN, Ole BAADSGAARD
-
Publication number: 20140141007Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.Type: ApplicationFiled: January 31, 2014Publication date: May 22, 2014Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
-
Patent number: 8728475Abstract: Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-? are disclosed, as are other methods.Type: GrantFiled: September 27, 2011Date of Patent: May 20, 2014Assignee: Biogen Idec MA Inc.Inventors: Linda C. Burkly, Timothy Zheng
-
Publication number: 20140134257Abstract: Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.Type: ApplicationFiled: March 8, 2013Publication date: May 15, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Neil P. DESAI, Markus RENSCHLER
-
Publication number: 20140134163Abstract: Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.Type: ApplicationFiled: January 16, 2014Publication date: May 15, 2014Inventor: Joseph P. Errico
-
Publication number: 20140134161Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders.Type: ApplicationFiled: July 5, 2012Publication date: May 15, 2014Applicant: SYKEHUSET SØRLANDET HFInventors: Christian Kersten, Marte Grønlie Cameron, Svein Mjåland
-
Publication number: 20140134133Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: November 10, 2013Publication date: May 15, 2014Applicants: Calitor Sciences, LLCInventor: Ning Xi
-
Publication number: 20140134160Abstract: The present invention provides compounds according to formula I: and pharmaceutically acceptable salts thereof. For compounds of formula I, R1 and R2 are independently selected from the group consisting of H, —C(?O)—(CH2)2-aryl, and —C(?O)—(CH2)n—C(?O)—NH-aryl. The subscript n is from 2 to 6. R3 is selected from the group consisting of H and —C(?O)—O—R4; and R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R1 and R2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided.Type: ApplicationFiled: November 12, 2013Publication date: May 15, 2014Applicant: BoYen Therapeutics, Inc.Inventor: Laurence I. Wu
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 8722041Abstract: This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity.Type: GrantFiled: June 16, 2011Date of Patent: May 13, 2014Assignee: Governors of the University of AlbertaInventors: Marit L. Sandvold, Finn Myhren, Carol E. Cass, James D. Young
-
Patent number: 8722046Abstract: In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.Type: GrantFiled: April 8, 2010Date of Patent: May 13, 2014Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Kei Amemiya, Dimiter S. Dimitrov, Xiaodong Xiao
-
Patent number: 8722042Abstract: The present invention relates to the use of MRI monitoring of ventricular enlargement rate as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen for Alzheimer's patients. Methods for treating Alzheimer's Disease and monitoring therapeutic effectiveness are provided.Type: GrantFiled: October 17, 2011Date of Patent: May 13, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventor: Norman R Relkin
-
Publication number: 20140127134Abstract: Embodiments provided herein relate to methods and compositions for treating or preventing cancer. More particularly, several embodiments are drawn to treating or preventing malignant mesothelioma with antagonists of HMGB1.Type: ApplicationFiled: June 7, 2012Publication date: May 8, 2014Inventors: Haining Yang, Michele Carbone, Marco E. Bianchi
-
Publication number: 20140127222Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: ApplicationFiled: January 3, 2014Publication date: May 8, 2014Applicant: ABBVIE BIOTECHNOLOGY LTD.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8715669Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: December 28, 2011Date of Patent: May 6, 2014Assignee: Novimmune SAInventors: Krzysztof Masternak, Olivier Leger
-
Patent number: 8715619Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: GrantFiled: February 11, 2013Date of Patent: May 6, 2014Assignee: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Patent number: 8715670Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.Type: GrantFiled: March 31, 2010Date of Patent: May 6, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
-
Patent number: 8715663Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: April 28, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Christopher J. Paszty, Hsieng Sen Lu
-
Patent number: 8715664Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: May 16, 2006Date of Patent: May 6, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg
-
Publication number: 20140120084Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.Type: ApplicationFiled: September 24, 2013Publication date: May 1, 2014Applicant: GENENTECH, INC.Inventors: Banmeet Anand, Eric Stefanich, Meina Tang, Jennifer Visich, Marna Williams, Sharon O'Byrne
-
Publication number: 20140120060Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.Type: ApplicationFiled: March 15, 2013Publication date: May 1, 2014Applicant: INFINITY PHARMACEUTICALS, INC.Inventors: Vito J. Palombella, Jeffrey L. Kutok
-
Publication number: 20140120089Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: December 19, 2013Publication date: May 1, 2014Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Jr., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Publication number: 20140120082Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.Type: ApplicationFiled: March 12, 2013Publication date: May 1, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Patent number: 8709418Abstract: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody comprising a heavy chain variable region that comprises SEQ ID NOS: 39, 40, and 41 and a light chain variable region that comprises SEQ ID NOS: 43, 44, and 45 or a fragment thereof as an active ingredient and having immunological reactivity with a CAPRIN-1 protein.Type: GrantFiled: February 4, 2011Date of Patent: April 29, 2014Assignee: Toray Industries, Inc.Inventors: Fumiyoshi Okano, Takanori Saito
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Patent number: 8703143Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.Type: GrantFiled: August 21, 2007Date of Patent: April 22, 2014Assignee: Philogen S.p.A.Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
-
Patent number: 8703138Abstract: Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein.Type: GrantFiled: April 13, 2010Date of Patent: April 22, 2014Assignee: The Feinstein Institute for Medical ResearchInventor: Ping Wang
-
Publication number: 20140105859Abstract: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicant: GILEAD SCIENCES, INC.Inventors: Manoj C. DESAI, Allen Yu HONG, Hongtao LIU, Randall W. VIVIAN, Lianhong XU
-
Publication number: 20140105892Abstract: Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations.Type: ApplicationFiled: December 16, 2013Publication date: April 17, 2014Applicant: BAYER HEALTHCARE LLCInventors: Jun Xiang, Xinghang Ma
-
Publication number: 20140105969Abstract: The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents.Type: ApplicationFiled: April 4, 2012Publication date: April 17, 2014Inventor: Harold J. Wanebo
-
Patent number: 8697077Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.Type: GrantFiled: May 2, 2012Date of Patent: April 15, 2014Assignee: The General Hospital CorporationInventor: Denise L. Faustman
-
Patent number: 8697071Abstract: The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by Fc?R is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: June 15, 2012Date of Patent: April 15, 2014Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sergey Gorlatov, Christopher Rankin, Nadine Tuaillon
-
Patent number: 8697076Abstract: Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides and epitopes in preparation of pharmaceutical compositions for the treatment of tauopathies, and uses of these antibodies, immunogenic peptides, epitopes and pharmaceutical compositions in the treatment of tauopathies are described. Also described are uses of these antibodies, immunogenic peptides, epitopes in diagnosis and monitoring of tauopathies.Type: GrantFiled: April 27, 2012Date of Patent: April 15, 2014Assignees: Northwestern University, Intellect Neurosciences Inc.Inventors: Lester I. Binder, Daniel G. Chain, Yifan Fu, Kristina Patterson
-
Publication number: 20140099320Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the molecules. The molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: Crucell Holland B.V.Inventors: Mark Throsby, Robert A. Kramer, Cornelis A. de Kruif
-
Publication number: 20140099254Abstract: The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease.Type: ApplicationFiled: December 14, 2013Publication date: April 10, 2014Applicant: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi